---
title: "Mizuho Securities Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278948210.md"
description: "Mizuho Securities has reaffirmed its Buy rating for Sarepta Therapeutics (SRPT) with a price target of $31.00, as stated by analyst Uy Ear. Ear, who specializes in the Healthcare sector, has an average return of 0.7% and a 37.36% success rate on his stock recommendations. Additionally, Sarepta received a Buy rating from Wedbush’s Yun Zhong on March 2, while Piper Sandler maintained a Hold rating yesterday."
datetime: "2026-03-12T21:25:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278948210.md)
  - [en](https://longbridge.com/en/news/278948210.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278948210.md)
---

# Mizuho Securities Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)

In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on Sarepta Therapeutics, with a price target of $31.00.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Ear covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Arcutis Biotherapeutics, and uniQure. According to TipRanks, Ear has an average return of 0.7% and a 37.36% success rate on recommended stocks.

In addition to Mizuho Securities, Sarepta Therapeutics also received a Buy from Wedbush’s Yun Zhong in a report issued on March 2. However, yesterday, Piper Sandler maintained a Hold rating on Sarepta Therapeutics (NASDAQ: SRPT).

### Related Stocks

- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [SRPU.US](https://longbridge.com/en/quote/SRPU.US.md)
- [SRPT.US](https://longbridge.com/en/quote/SRPT.US.md)

## Related News & Research

- [Goldman Sachs Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)](https://longbridge.com/en/news/283014601.md)
- [BUZZ-Cancer biotech Adlai Nortye jumps after $150 mln equity financing](https://longbridge.com/en/news/282996483.md)
- [Alkermes: Positive Alixorexton Phase 2 Data in Narcolepsy Type 1 Support Advancement to Phase 3 and Reinforce Buy Rating](https://longbridge.com/en/news/283016564.md)
- [Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham](https://longbridge.com/en/news/282904330.md)
- [BUZZ-Allogene tumbles on $175 mln stock offering after cancer therapy data](https://longbridge.com/en/news/282722450.md)